Ou, Zhen-Yi Andy
Byrne, Lauren M.
Rodrigues, Filipe B.
Tortelli, Rosanna
Johnson, Eileanoir B.
Foiani, Martha S.
Arridge, Marzena
De Vita, Enrico
Scahill, Rachael I.
Heslegrave, Amanda
Zetterberg, Henrik
Wild, Edward J.
Funding for this research was provided by:
Hereditary Disease Foundation
Huntington's Disease Society of America
Wellcome Trust (Wellcome/EPSRC Centre for Medical Engineering [WT 203148/Z/16/Z], Wellcome Collaborative Award in Science 200181/Z/1)
European Research Council
Horizon 2020 Framework Programme
Innovative Medicines Initiative (EMIF grant)
Swedish Research Council
Swedish State Support for Clinical Research
CHDI Foundation
F. Hoffman-La Roche
Medical Research Council
Article History
Received: 17 November 2020
Accepted: 18 January 2021
First Online: 10 February 2021
Competing interests
: ZAO, LMB, FBR, MF, RT, EBJ, RIS, AH, HZ, EJW are University College London employees. MA is a University College London Hospitals NHS Foundation Trust employee. EDV is a King’s College London employee. LMR has provided consultancy services to GLG, F. Hoffmann-La Roche Ltd, Genentech and Annexon. FBR has provided consultancy services to GLG and F. Hoffmann-La Roche Ltd. RIS has undertaken consultancy services for Ixitech Ltd. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). EJW reports grants from Medical Research Council, CHDI Foundation, and F. Hoffmann-La Roche Ltd during the conduct of the study; personal fees from Hoffman La Roche Ltd, Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda and Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals.